. 2017 Mar 31;87(4):254–263. doi: 10.1159/000467393

Table 1.

Baseline characteristics

	Total cohort		Subgroups by sex				Subgroups by puberty
	n	(n = 101)	n	female (n = 47)	n	male (n = 54)	n	prepubertal (n = 43)	n	pubertal (n = 57)
Age, years	101	10.9 (3.1)	47	10.3 (2.9)	54	11.4 (3.1)	43	8.4 (1.9)	57	12.8 (2.3)
BA, years	101	11.8 (2.1)	47	10.9 (2.9)	54	12.6 (2.9)	43	9.6 (2.0)	57	13.5 (2.5)
BA SDS	101	1.2 (1.1)^*	47	0.8 (1.2)^*	54	1.4 (1.0)^*	43	1.6 (1.1)^*	57	0.8 (1.1)^*
Caucasian^a	101	64 (63.4)	47	27 (57.4)	54	37 (68.5)	43	19 (44.2)	57	44 (77.2)
Height SDS	101	0.6 (1.0)^*	47	0.4 (1.0)^*	54	0.7 (1.1)^*	43	0.8 (1.0)^*	57	0.4 (1.0)^*
BMI SDS	101	3.4 (0.6)^*	47	3.1 (0.5)^*	54	3.6 (0.7)^*	43	3.6 (0.7)^*	57	3.2 (0.5)^*
Fasting insulin, mU/L^b	101	12 (6/18)	47	11 (6/19)	54	12 (7/16)	43	7 (4/11)	57	16 (10/26)
HOMA-IR^b	101	2.1 (1.3/3.7)	47	2.1 (1.3/3.9)	54	2.3 (1.3/3.5)	43	1.3 (0.8/2.0)	57	2.4 (2.1/4.8)
AUC insulin, mU/L^b	94	305 (202/468)	43	267 (186/454)	51	309 (210/482)	40	211 (159/397)	53	362 (238/544)
Oestradiol SDS	50	0.0 (1.4)	21	−0.2 (1.1)	29	0.1 (1.5)		−	39	0.0 (1.3)
Testosterone SDS^b	64	−0.6 (–1.2/0.3)^*	28	−0.7 (–2.7/1.6)	36	−0.6 (–1.1/0.0)^*		−	51	−0.7 (–1.3/0.4)^*
DHEAS SDS^b	96	0.4 (0.0/1.0)^*	45	0.3 (–0.8/0.7)	51	0.4 (0.1/1.0)^*	41	0.4 (–0.3/1.1)	54	0.3 (0.0/0.9)^*
SHBG SDS^b	96	−1.9 (–2.4/–1.1)^*	46	−1.9 (–1.2/–2.2)^*	50	−1.9 (–2.4/–1.1)^*	40	−1.5 (–2.2/–0.7)^*	55	−2.0 (–2.4/–1.4)^*
Androstenedione, nmol/L^b	100	2.25 (1.30/3.60)	47	2.40 (1.20/4.10)	53	2.20 (1.30/3.30)	42	1.25 (0.78/2.23)	57	3.00 (2.15/4.50)

Data are expressed as mean (standard deviation) unless otherwise stated. Data on oestradiol SDS and testosterone SDS are on the age group of ≥9 years. SDS, standard deviation score; BA, bone age; BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance; AUC, area under the curve; DHEAS, dehydroepiandrosterone sulphate; SHBG, sex hormone-binding globulin.

n (%).

Median (interquartile range).

SDS, p < 0.05.